Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma

Draft scope assessment: unclear. Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Survival without measurable progression of lymphoma estimated according to the Kaplan-Meier method

Source null

→

secondary · POSTED

Percentage of patients remaining alive estimated according to the Kaplan-Meier method

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-non-hodgkin-lymphoma-zydelig-b71fbc34
nct id: NCT00244855
trial label: Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma
applicability: unclear
applicability note: Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 2
harms Count: 2
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-zydelig-b71fbc34
nct id
NCT00244855
outcome key
om-0000
source section id
NCT00244855-om-0000
source outcome index
0
endpoint
Progression-free Survival
endpoint definition
Survival without measurable progression of lymphoma estimated according to the Kaplan-Meier method
time origin
At 3 and 6 months after enrollment
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-zydelig-b71fbc34
nct id
NCT00244855
outcome key
om-0001
source section id
NCT00244855-om-0001
source outcome index
1
endpoint
Survival
endpoint definition
Percentage of patients remaining alive estimated according to the Kaplan-Meier method
time origin
At 6 months, 12 months and 24 months after enrollment
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-zydelig-b71fbc34
nct id
NCT00244855
outcome key
om-0000
arm key
OG000
arm label
Previous Treatment
regimen
Patients received previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity. pharmacological study: Correlative studies rituximab: Given IV dexamethasone: Given IV laboratory biomarker analysis: Correlative studies
analyzed count
7
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00244855-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-zydelig-b71fbc34
nct id
NCT00244855
outcome key
om-0000
arm key
OG001
arm label
No Previous Treatment
regimen
Patients received no previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity. pharmacological study: Correlative studies rituximab: Given IV dexamethasone: Given IV laboratory biomarker analysis: Correlative studies
analyzed count
25
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00244855-om-0000#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-zydelig-b71fbc34
nct id
NCT00244855
outcome key
om-0001
arm key
OG000
arm label
No Previous Treatment
regimen
Patients received no previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity. pharmacological study: Correlative studies rituximab: Given IV dexamethasone: Given IV laboratory biomarker analysis: Correlative studies
analyzed count
7
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00244855-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-zydelig-b71fbc34
nct id
NCT00244855
outcome key
om-0001
arm key
OG001
arm label
Previous Treatment
regimen
Patients received previous treatment. Patients enrolled in the trial received dexamethasone IV and rituximab IV once weekly. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity. pharmacological study: Correlative studies rituximab: Given IV dexamethasone: Given IV laboratory biomarker analysis: Correlative studies
analyzed count
25
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00244855-om-0001#groups/OG001

harms

release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-zydelig-b71fbc34
nct id
NCT00244855
harm key
EG000
source section id
NCT00244855-ae
event group key
EG000
event group label
Previous Treatment
serious affected
0
serious at risk
7
other affected
5
other at risk
7
frequency threshold
4
collection period
6 months
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-zydelig-b71fbc34
nct id
NCT00244855
harm key
EG001
source section id
NCT00244855-ae
event group key
EG001
event group label
No Previous Treatment
serious affected
0
serious at risk
25
other affected
16
other at risk
25
frequency threshold
4
collection period
6 months
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice